10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

VEGI (Human); VEGI-192

Catalog # PVGS1016

Product Information

Species	Human
Sequence	The sequence of the first five N-terminal amino acids has been found to be Met-Gln-Leu-Thr-Lys.
Purity	The purity of Recombinant Human VEGI-192 is greater than 95.0%, as determined by the following methods: (a) RP-HPLC analysis (b) Reducing and non-reducing SDS-PAGE silver-stained gel analysis
Endotoxin Level	The endotoxin level of Recombinant Human VEGI-192 is below 0.1 ng/ μg (1 IEU/ μg) of rHuVEGI.
Formulation	Recombinant Human VEGI-192 is lyophilized after extensive dialysis against 0.5 M NaCl, 50 mM Tris-HCl buffer, pH 7.5.
Reconstitution	It is recommended that the lyophilized VEGI-192 be reconstituted in sterile 18 MΩ-cm H_2O not less than 100 μg/ml, which can then be further diluted to other aqueous solutions.

Additional Information

Target Background	Vascular endothelial growth inhibitor (VEGI; TNFSF-15) is a new member of the tumor necrosis factor family. VEGI is predominantly an endothelial cell-specific gene, and recombinant VEGI is a potent inhibitor of endothelial cell proliferation, angiogenesis and tumor growth. VEGI exerts two activities on endothelial cells: early G1 arrest of G0/G1-cells responding to growth stimuli, and programmed death of proliferating cells. These activities are highly specific to endothelial cells. VEGI is also able to regulate the expression of several important genes involved in angiogenesis. These findings are consistent with the view that VEGI functions as an autocrine cytokine to inhibit angiogenesis and stabilize the vasculature. Vascular Endothelial Growth Inhibitor (VEGI), human, produced in E. coli, is a single, non-glycosylated polypeptide chain containing 192 amino acids and having a molecular mass of 21,858 Da.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.